Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies.
Gauthier J, Bezerra ED, Hirayama AV, Fiorenza S, Sheih A, Chou CK, Kimble EL, Pender BS, Hawkins RM, Vakil A, Phi TD, Steinmetz RN, Jamieson AW, Bar M, Cassaday RD, Chapuis AG, Cowan AJ, Green DJ, Kiem HP, Milano F, Shadman M, Till BG, Riddell SR, Maloney DG, Turtle CJ.
Gauthier J, et al. Among authors: bezerra ed.
Blood. 2021 Jan 21;137(3):323-335. doi: 10.1182/blood.2020006770.
Blood. 2021.
PMID: 32967009
Free PMC article.
Clinical Trial.